AN1792

AN1792

A synthetic form of the 42-residue A beta protein seen in Alzheimer’s disease (AD) brains. It prevents appearance of amyloid plaques and the neuropathology characteristic of autosomal dominant AD in young PDAPP mice; immunisation of older mice with established AD-like pathology resulted in a marked reduction or stopped disease progression.
AN-792 made it to early trials as an immune therapy for AD; some patients developed CNS inflammation; trials were halted in 2002.
References in periodicals archive ?
Bapineuzumab was the first antibody to be tested in clinical trials after the termination of the AN1792 clinical study.
The vaccine, known as EB101, was patented in 2010 in the United States but, when scientists tried to compare it with AN1792, a vaccine currently approved by the US Food and Drug Administration (FDA), they discovered side effects that resulted in the analysis being dropped.
The first active immunization clinical trial, which tested AN1792 in AD patients, was halted when a subset of patients developed meningoencephalitis.
Plc and Wyeth (Madison NJ) known as AN1792 may have removed signature plaques from patients' brains, but they all developed severe dementia anyway.
Clive Holmes of Moorgreen Hospital in Southampton in Britain, involved a six-year follow-up of AN1792.
Those hopes were short-lived, however, when 12 volunteers fell ill with brain inflammation that might be linked to the AN1792 tests.
The first vaccine candidate for AD was AN1792, developed by Elan.
Significant efforts have been made to understand why AN1792 produced an adverse response in some patients, and to study other requirements such as the need to elicit an adequate immune response (i.
of the University of Southampton (England), studied the tau effects of another Abeta immunotherapy agent called AN1792, which was pulled from development in 2002 after 6% of the patients who received it developed serious brain inflammation and subsequent brain atrophy.
A report published recently in Nature Medicine summarizes the neuropathology of a patient with Alzheimer's disease that participated in the Phase 1 study using AN1792.